Roche's antiobesity drug clears hurdle; U.S. panel's marketing clearance boosts stock

Article Abstract:

Roche Holding Ltd (Basel, Switzerland) gained marketing clearance for its antiobesity drug Xenical on Apr 23, 1999, causing the company's stock to jump 4.3%. Xenical was launched in Europe in Sep 1998, but its US launch was delayed while a possible breast cancer link was investigated. Marketing is expected to begin in early May 1999. One analyst expect Xenical sales to total 2.3 billion francs by 2005. For its first few years of release, Xenical is expected to dominate the market for obesity treatments, along with BASF AG's Meridia.

Comment:

Roche Holding Ltd (Basel, Switzerland) gains marketing approval for the antiobesity drug Xenical

United States, Switzerland, Anorexigenics, Laws, regulations and rules, Appetite depressants, United States. Food and Drug Administration, Roche Holding Ltd., Xenical (Medication)

---

British Biotech shares fall by 16% after drug trial

Article Abstract:

Shares in British Biotech Plc fell 16% after the company's flagship anticancer drug marimastat failed expected goals in its clinical trial in treating advanced pancreatic cancer. The scientific setback rekindled questions about the company's survival and sent British Biotech shares down to 21.75 pence (35.3 cents), down 4.25 pence, in London trading. As recently as May 1997, British Biotech's stock peaked at 270.5 pence, but has steadily decreased due to disappointing results for experimental drugs and management turmoil.

United Kingdom, Sales, profits & dividends, Finance, British Biotech PLC

---

European patients fight for access to cancer drugs

Article Abstract:

This article chronicles the difficulties European patients experience in getting anticancer drugs. In several countries, the U. K. for example, government agencies refuse to pay for certain drugs or restrict the number of prescriptions that doctors may issue.

Europe, Care and treatment, Cancer, Cancer treatment

Similar abstracts:

• Abstracts: Fininvest SpA's listing expected to face hurdles. EPlanet shares fall amid cash crunch; buyer is sought. Art'e' plans to bring modern art - and itself public
• Abstracts: China's telecom forays squeeze struggling rivals. Unease about U.S. role in global recovery grows. German Economy grew by 2.3% In First Quarter
• Abstracts: Military recruiters face a tough sell in job-rich U.S. Breaking a taboo, army confronts guilt after combat. Generals, entrepreneurs start sites for soldiers
• Abstracts: EU investigates Coke on antitrust suspicion. U.K. referendum ups the ante for EU: Blair's policy reversal on constitution puts pressure on France, others
• Abstracts: Investors seek strategy answers from BAA chief. BAA's profit seen hurt by pound, rail service losses

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.